RBC Capital Markets Adjusts Price Target on Verastem
RBC Capital Markets lowered its price target on Verastem, Inc. while maintaining an Outperform rating.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
RBC Capital Markets lowered its price target on Verastem, Inc. while maintaining an Outperform rating.
Verastem Oncology announced its financial results for the third quarter ended September 30, 2026, reporting $24.0 million in product revenue and providing updates on its clinical pipeline.
Filed: 2026-11-05 AccNo: 0001104659-26-123386 Size: 12 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Verastem Oncology management is scheduled to present at three upcoming healthcare investor conferences in November 2026.
Novocure and Verastem Oncology have entered into a clinical trial collaboration and supply agreement to evaluate the combination of Tumor Treating Fields (TTFields) therapy with chemotherapy and Verastem's KRAS G12D inhibitor, VS-7375.
The colorectal cancer market is projected to grow significantly from 2026-2036, driven by rising incidence rates, increased disease awareness, and adoption of targeted therapies and immunotherapies. The market was valued at approximately USD 13 billion in 2025. Key growth drivers include emerging therapies targeting KRAS G12C, NTRK fusions, and PIK3CA mutations, with major pharmaceutical companies launching innovative treatments. The US accounts for the largest market share among the 7 major markets analyzed.